Evidence map›Paper›PMID 40093888›Full record

ArticleTheranostics2025

Sex- and age-specific sensitivities of the endocannabinoid system in Alzheimer's disease revealed by PET imaging with [

Anna Pees, Christopher Daniel Morrone, Junchao Tong, Jian Rong, Tuo Shao, Darcy Wear, Steven H Liang, Wai Haung Yu, Neil Vasdev

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna PeesAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.
Christopher Daniel MorroneAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.
Junchao TongAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.
Jian RongDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States.
Tuo ShaoJiangsu Key Laboratory of Infection and Immunity, Suzhou Medical College, Suzhou, China.
Darcy WearAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, United States.
Wai Haung YuDepartment of Pharmacology & Toxicology, University of Toronto, Ontario, Canada.
Neil VasdevAzrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH), Toronto, ON, Canada, M5T 1R8.

Funding

New PET tracers for neuroimaging of FAAH in endocannabinoid signalingK01DA038000 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2014 to 2018
$927k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR33DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2019 to 2021
$851k
MAGL PET tracer-guided prognosis and neuroprotective therapy for Alzheimer's diseaseR03AG063290 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2019 to 2020
$495k
Novel PET Tracers for Imaging Monoacylglycerol Lipase in Endocannabinoid SignalingR21DA043507 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2017 to 2018
$425k
NIA NIH HHS R03 AG063290NIDA NIH HHS K01 DA038000NIDA NIH HHS R21 DA043507NIDA NIH HHS R33 DA043507
6 · The paper itself

Abstract

The endocannabinoid system is a critical brain signaling pathway that is dysregulated in various brain disorders, including Alzheimer's disease (AD). Cannabinoid-targeted therapies and imaging approaches have gained increasing interest; however, the biological impact of the endocannabinoid system in disease needs further validation. We aimed to study changes in cannabinoid receptor 1 (CB1) and monoacylglycerol lipase (MAGL), components of endocannabinoid signaling and degradation, in a mouse model of AD by PET imaging.

Indexed as

Alzheimer DiseaseEndocannabinoidsAge FactorsAmyloid beta-Protein PrecursorAnimalsBrainDisease Models, AnimalFemaleFluorine RadioisotopesHumansMaleMiceMice, TransgenicMonoacylglycerol LipasesPositron-Emission TomographyPositron Emission Tomography Computed TomographyAmyloid beta-Protein PrecursorEndocannabinoidsFluorine RadioisotopesMonoacylglycerol LipasesReceptor, Cannabinoid, CB1Alzheimer's diseasecannabinoid receptor 1endocannabinoid systemmonoacylglycerol lipasePET

Identifiers

PMID40093888
PMCPMC11905134

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.